COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB plus PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)

被引：0
|
作者：
Arreola Ornelas, H. [1 ,2 ]
Rosado Buzzo, A. [1 ]
Garcia, L. [1 ]
Camacho, L. M. [1 ]
Lechuga, D. [3 ]
机构：
[1] OikoSalud, Mexico City, DF, Mexico
[2] Fdn Mexicana Salud, Mexico City, DF, Mexico
[3] Roche Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A451 / A451
页数：1
相关论文
共 50 条
  • [11] Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand
    Katanyoo, Kanyarat
    Chaikledkaew, Usa
    Chandeying, Nutthaporn
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [12] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [13] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Alberto J. Montero
    Kiran Avancha
    Stefan Glück
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2012, 132 : 747 - 751
  • [14] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Montero, Alberto J.
    Avancha, Kiran
    Glueck, Stefan
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 747 - 751
  • [15] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Hao, Chunfang
    He, Lihong
    Dong, Guolei
    Wang, Xiaorui
    Jia, Yongsheng
    Zhang, Li
    CANCER RESEARCH, 2015, 75
  • [16] Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
    Albain, Kathy S.
    Nag, Shona M.
    Calderillo-Ruiz, German
    Jordaan, Johann P.
    Llombart, Antonio C.
    Pluzanska, Anna
    Rolski, Janusz
    Melemed, Allen S.
    Reyes-Vidal, Jose M.
    Sekhon, Jagdev S.
    Simms, Lorinda
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3950 - 3957
  • [17] Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China
    Tang, Wen-Xi
    Shao, Rong-Jie
    Wang, Jingshu
    Scherrer, Emilie
    Ma, Ai-Xia
    Aguiar-Ibanez, Raquel
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 27 : 99 - 107
  • [18] Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer.
    Gradishar, W
    Vishalpura, T
    Franklin, M
    Bramley, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S220 - S221
  • [19] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [20] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345